Advice
In the absence of a submission from the holder of the marketing authorisation:
 
panitumumab (Vectibix®)is not recommended for use within NHS Scotland.
 
Indication under review: treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX;  in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
 
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice38KB (PDF)

Download

Medicine details

Medicine name:
panitumumab (Vectibix)
SMC ID:
769/12
Indication:
Metastatic colorectal cancer (mCRC)
Pharmaceutical company
Amgen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Superseded
Date advice published:
13 February 2012